Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Two-wheeler majors bounce back with strong double digit growth in May
- What can we expect from the 54th GST meeting on September 9? Insurance premiums, online gaming likely to get attention
- India needs to boost maize production, adjust pricing for grain ethanol: report
- India:Higher FDI cap in insurance could attract fund inflows of more than US$2bn
